-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 11, Real Biology announced that the Drug Evaluation Center of the State Drug Administration has approved Gen-725 tablets from Henan True Biotechnology Co., Ltd. to conduct a phase IIa clinical trial to treat malignant hematomas. The approved phase IIa clinical trial will further evaluate the safety and initial efficacy of azvudine in patients with malignant hematomas based on preliminary research.

Zhitongcaijing·12/11/2025 02:01:05
Listen to the news
On December 11, Real Biology announced that the Drug Evaluation Center of the State Drug Administration has approved Gen-725 tablets from Henan True Biotechnology Co., Ltd. to conduct a phase IIa clinical trial to treat malignant hematomas. The approved phase IIa clinical trial will further evaluate the safety and initial efficacy of azvudine in patients with malignant hematomas based on preliminary research.